Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Re:NewCell in connection with a directed share issue (1)
Mandate

Vinge has advised Re:NewCell in connection with a directed share issue

October 31, 2022 Capital Markets and Public M&A

Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 158 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Founded by innovators from Stockholm’s KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) is a multi-award-winning sustaintech company based in Sweden. The company’s vision is to make fashion circular.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge and Johannes Akyol. Henrik Ossborn and Agaton Lindgren provided financing advice.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025